Once again, reference being made in US article b/w Dendreon and...

Once again, reference being made in US article b/w Dendreon and Prima.Scroll down and the reference is made under the Dendreon article.
The other point to note is the upcoming results on Stimuvax... I think Kbear ( or another poster) mentioned the relevance of this trial - as previously flagged by MR.
I think the results are due end of Feb12 ..it would be great if the relevant poster could confirm this ?

http://www.dailydoseequities.com/blog/tag/prr

THEN ...go back up again and click on THE EDITOR just under the Prima article heading.
Scroll down again and more PPR coverage.
Prima ( editor reference PPRO)included in Table of all US Biotechs.

http://www.dailydoseequities.com/blog/author/dailydoseequities

No doubt the science (and trials) are by the far the MOST important criteria for PRR. But I can also identify the dynamism that Nasdaq membership will bring to the table ..due to the anticipated and expected connection to be made by US investors to Dendreon.

When I look at PRR and DNDN , the 1st thing that catches my eye is the difference in market caps.Once US investors poke a bit more and understand the Cvac technology, IMO - the market cap comparison will be highlighted even further.

Staying power and patience is my view when it comes to Biotech stocks.

Good luck to all holders and please DYOR before doing anything.